RNAi Therapeutics News and Research

RSS
RNA interference (RNAi) was discovered less than a decade ago and already there are human clinical trials in progress or planned. A major advantage of RNAi versus other anti-sense based approaches for therapeutic applications is that it utilizes cellular machinery that efficiently allows targeting of complementary transcripts, often resulting in highly potent down-regulation of gene expression.
Alnylam Pharmaceuticals presents new data related to its overall delivery research efforts

Alnylam Pharmaceuticals presents new data related to its overall delivery research efforts

Alnylam Pharmaceuticals and Roche team up to develop specific RNAi therapeutic products

Alnylam Pharmaceuticals and Roche team up to develop specific RNAi therapeutic products

Arrowhead Research updates its shareholders

Arrowhead Research updates its shareholders

Alnylam Pharmaceuticals presents new data from its transthyretin-mediated amyloidosis program

Alnylam Pharmaceuticals presents new data from its transthyretin-mediated amyloidosis program

Alnylam Pharmaceuticals announces participation in a $2.4M cardiovascular disease research grant

Alnylam Pharmaceuticals announces participation in a $2.4M cardiovascular disease research grant

United States Patent and Trademark Office allows a patent application within ‘Esau’ patent family

United States Patent and Trademark Office allows a patent application within ‘Esau’ patent family

KOKEN receives license to manufacture and provide RNAi research products under Kreutzer-Limmer patent family

KOKEN receives license to manufacture and provide RNAi research products under Kreutzer-Limmer patent family

RXi Pharmaceuticals presents new preclinical data from its advanced RNAi therapeutic platform

RXi Pharmaceuticals presents new preclinical data from its advanced RNAi therapeutic platform

RXi receives USPTO notices of allowance for certain siRNA sequence-specific patent applications

RXi receives USPTO notices of allowance for certain siRNA sequence-specific patent applications

RXi Pharmaceuticals acquires self-delivering rxRNA technology platform from Advirna

RXi Pharmaceuticals acquires self-delivering rxRNA technology platform from Advirna

JPO to grant patent from the Tuschl III patent series

JPO to grant patent from the Tuschl III patent series

RXi Pharmaceuticals to present in vivo data of rxRNA compounds

RXi Pharmaceuticals to present in vivo data of rxRNA compounds

Alnylam and Medtronic announce pre-clinical research findings from their Huntington’s disease program

Alnylam and Medtronic announce pre-clinical research findings from their Huntington’s disease program

Zabecor Pharmaceuticals initiates Phase II clinical trial of its Excellair asthma drug

Zabecor Pharmaceuticals initiates Phase II clinical trial of its Excellair asthma drug

USPTO allows Isis an additional patent for single-stranded RNAi technology

USPTO allows Isis an additional patent for single-stranded RNAi technology

EPO issues grant for a patent in Kreutzer-Limmer III patent series

EPO issues grant for a patent in Kreutzer-Limmer III patent series

Alnylam and Tekmira to collaborate on RNAi therapeutics

Alnylam and Tekmira to collaborate on RNAi therapeutics

Intradigm issued RNA interference (RNAi) patent covering potent siRNA sequence

Intradigm issued RNA interference (RNAi) patent covering potent siRNA sequence

Oral delivery system for RNAi therapeutics

Oral delivery system for RNAi therapeutics

Intradigm receives notice of allowance for key RNA interference patent covering potent siRNA sequence

Intradigm receives notice of allowance for key RNA interference patent covering potent siRNA sequence